ClinicalTrials.gg
CompletedNCT03291067Updated Jan 23, 2026Results posted

MT-8554 for Reduction of Vasomotor Symptoms in Postmenopausal Women

A Phase 2 interventional study of MT-8554 1mg and MT-8554 5mg in Menopause Hot Flashes, sponsored by Tanabe Pharma America, Inc.. Completed at 63 sites in United States. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-23.

Sponsored by Tanabe Pharma America, Inc. (part of Tanabe Pharma Corporation) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
375
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 193 studies in Hot Flashes with a site in United States — 26 open to participants now, 27 under way, 2 of them phase 3. Hot Flashes · United States.

Enrollment
24th of 180
375 · median 84
Started
2017
with 6 others
Phase 2
41 of 193
6 open now
Registered
136th of 193
by date

Among the 193 studies in Hot Flashes with a site in United States, this one is the 24th largest by enrollment of the 180 interventional ones that give a count, is one of 7 that started in 2017, is one of 41 in phase 2, and was the 136th registered.

Hot Flashes

339 studies on the registry are indexed under Hot Flashes; 56 are open to participants now.

Browse Hot Flashes studies →

Open to participants now

26 of the 193 studies in Hot Flashes with a site in United States are open now. Recruiting first, the newest first:

21 more — sign in →

All 26 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 36 Hot Flashes studies recruiting now, 13 (36%) set no upper age limit and 21 (58%) stop at 75 or younger; 2 take children under 18; 11 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 193 studies in Hot Flashes with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to assess the efficacy and safety of MT-8554 for treatment of vasomotor symptoms (VMS) associated with menopause.

Read the detailed description

This is a Phase II randomized, double-blind, placebo-controlled study for dose selection in postmenopausal women with moderate to severe VMS, defined as follows:

  • Moderate: sensation of heat with sweating, able to continue activity
  • Severe: sensation of heat with sweating, causing cessation of activity This study is comprised of a screening period, a run-in period and a 12-week double-blind treatment period.
03

Conditions studied

  • Menopause Hot Flashes

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Additional screening criteria check may apply for qualification:

  • Provide written to participate in this study
  • Spontaneous amenorrhea for ≥12 months; or spontaneous amenorrhea for at least 6 months and with follicle stimulating hormone (FSH) levels >40 mIU/mL; or documented bilateral salpingo oophorectomy ≥6 weeks, with or without hysterectomy
  • 7 or more moderate to severe VMS per day, or 50 or more moderate to severe VMS per week
  • Have a consistent bedtime on at least 5 nights per week
  • Mean VMS frequency during the Placebo Run in period does not drop by more than 50% from the mean level reported for 2 weeks during the Screening period
  • VMS diary compliance >50%
  • In the Investigator's opinion, subject is able to understand the nature of the study and any risk involved in participation, and is willing to cooperate and comply with the protocol restrictions and requirements

Exclusion criteria

Exclusion Criteria:

Additional screening criteria check may apply for qualification:

  • History of any cancer within 5 years except for basal cell carcinoma
  • History of undiagnosed abnormal vaginal bleeding
  • History of , or
  • History of psychiatric illness, excessive alcohol intake or use of recreational drugs who are unsuitable for study enrollment and compliance
  • Presence or history of severe adverse reaction or allergy to any drug
  • Peripheral vascular disease or disorders with associated vasculopathies
  • conditions which could interfere with the objectives of the study or the safety of the subject, as judged by the Investigator
  • Endometrial thickness of >=5 mm as measured by transvaginal ultrasound
  • Abnormal result from baseline endometrial (i.e., endometrial hyperplasia or endometrial cancer)
  • (AST), alanine aminotransferase (ALT), or total ≥2.0 × (ULN) above the reference range
  • Subjects of
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
375 participants (actual)

Study arms

  • Experimental
    MT-8554 1mg

    Drug: MT-8554 1mg

  • Experimental
    MT-8554 5mg

    Drug: MT-8554 5mg

  • Experimental
    MT-8554 10mg

    Drug: MT-8554 10mg

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

  • MT-8554 1mg QD, oral, 12 weeks

  • MT-8554 5mg QD, oral, 12 weeks

  • MT-8554 10mg QD, oral, 12 weeks

  • DrugPlacebo

    Placebo QD, oral, 12 weeks

06

What researchers measure

Primary outcomes

  1. Change From Baseline in the Average Daily Frequency of Moderate to Severe VMS at Weeks 4 and 12

    The average daily frequency of moderate to severe VMS at a time point (Baseline, Weeks 4 and 12) was the average of the frequency of moderate to severe VMS of available diary days in a 7-day window. Changes in the average daily frequency of moderate to severe VMS at Week 4 and Week 12 compared to baseline were evaluated.

    Time frame: Baseline, Weeks 4 and 12

  2. Change From Baseline in the Average Daily Severity Score of Mild to Severe VMS at Weeks 4 and 12

    The daily severity score of VMS was defined as (2xFmo + 3xFse)/(Fmo + Fse) for baseline, and (1xFmi + 2xFmo + 3xFse)/(Fmi + Fmo + Fse) for Weeks 4 and 12, where Fmi, Fmo, and Fse were the daily frequencies of mild, moderate, and severe VMS, respectively. The average daily severity score of mild to severe VMS at a time point (Baseline, Week 4 and Week 12) was the average of the daily severity of available diary days in the corresponding 7-day window. The severity score of VMS ranged from 0 (lowest severity) to 3 (highest severity). Change in the average daily severity score of mild to severe VMS at Week 4 and Week 12 compared to baseline were evaluated.

    Time frame: Baseline, Weeks 4 and 12

Secondary outcomes

  1. Percentage of Responders at Weeks 4 and 12

    Subjects with cutoff number or greater reduction in the average daily frequency of moderate and severe VMS compared to baseline. The cutoff number was calculated using anchor-based method. The cutoff number was defined as numerical value to maximize the sensitivity and the specificity, using Patient Global Impression of Change (PGIC) as the anchor.

    Time frame: Week 4 and Week 12

  2. Change From Baseline in the Insomnia Severity Index at Week 4 and Week 12

    The Insomnia Severity Index was a self-rated, 7-item validated sleep scale that measured clinical insomnia severity. The total score ranged from 0-28 where higher values indicated increased severity of insomnia.

    Time frame: Baseline, Weeks 4 and 12

07

Results

Posted Jan 4, 2022

Participant flow

Participant flow — Overall Study
MilestoneMT-8554 1mgMT-8554 5mgMT-8554 10mgPlacebo
Started94929494
Treated95909390
Completed84786177
Not completed10143317
Withdrew: Adverse event02173
Withdrew: Lost to follow-up2101
Withdrew: Physician decision0010
Withdrew: Protocol violation5342
Withdrew: Withdrawal by subject3475
Withdrew: Other0446

Outcome measures

PrimaryChange From Baseline in the Average Daily Frequency of Moderate to Severe VMS at Weeks 4 and 12

The average daily frequency of moderate to severe VMS at a time point (Baseline, Weeks 4 and 12) was the average of the frequency of moderate to severe VMS of available diary days in a 7-day window. Changes in the average daily frequency of moderate to severe VMS at Week 4 and Week 12 compared to baseline were evaluated.

Time frame:
Baseline, Weeks 4 and 12
Reported as:
Least squares mean · VMS per day
Change From Baseline in the Average Daily Frequency of Moderate to Severe VMS at Weeks 4 and 12
VMS per dayMT-8554 1mgMT-8554 5mgMT-8554 10mgPlacebo
Week 4-1.92 ± 0.609-2.75 ± 0.705-2.75 ± 0.734-1.39 ± 0.705
Week 12-2.91 ± 0.690-3.11 ± 0.780-3.38 ± 0.821-2.78 ± 0.779
PrimaryChange From Baseline in the Average Daily Severity Score of Mild to Severe VMS at Weeks 4 and 12

The daily severity score of VMS was defined as (2xFmo + 3xFse)/(Fmo + Fse) for baseline, and (1xFmi + 2xFmo + 3xFse)/(Fmi + Fmo + Fse) for Weeks 4 and 12, where Fmi, Fmo, and Fse were the daily frequencies of mild, moderate, and severe VMS, respectively. The average daily severity score of mild to severe VMS at a time point (Baseline, Week 4 and Week 12) was the average of the daily severity of available diary days in the corresponding 7-day window. The severity score of VMS ranged from 0 (lowest severity) to 3 (highest severity). Change in the average daily severity score of mild to severe VMS at Week 4 and Week 12 compared to baseline were evaluated.

Time frame:
Baseline, Weeks 4 and 12
Reported as:
Least squares mean · VMS severity score per day
Change From Baseline in the Average Daily Severity Score of Mild to Severe VMS at Weeks 4 and 12
VMS severity score per dayMT-8554 1mgMT-8554 5mgMT-8554 10mgPlacebo
Week 4-0.302 ± 0.0609-0.407 ± 0.0714-0.305 ± 0.0740-0.316 ± 0.0712
Week 12-0.374 ± 0.0725-0.481 ± 0.0822-0.433 ± 0.0864-0.388 ± 0.0819
SecondaryPercentage of Responders at Weeks 4 and 12

Subjects with cutoff number or greater reduction in the average daily frequency of moderate and severe VMS compared to baseline. The cutoff number was calculated using anchor-based method. The cutoff number was defined as numerical value to maximize the sensitivity and the specificity, using Patient Global Impression of Change (PGIC) as the anchor.

Time frame:
Week 4 and Week 12
Reported as:
Number · percentage of subjects
Percentage of Responders at Weeks 4 and 12
percentage of subjectsMT-8554 1mgMT-8554 5mgMT-8554 10mgPlacebo
Week 431.852.436.136.0
Week 1244.460.554.154.1
SecondaryChange From Baseline in the Insomnia Severity Index at Week 4 and Week 12

The Insomnia Severity Index was a self-rated, 7-item validated sleep scale that measured clinical insomnia severity. The total score ranged from 0-28 where higher values indicated increased severity of insomnia.

Time frame:
Baseline, Weeks 4 and 12
Reported as:
Least squares mean · units on a scale
Change From Baseline in the Insomnia Severity Index at Week 4 and Week 12
units on a scaleMT-8554 1mgMT-8554 5mgMT-8554 10mgPlacebo
Week 4-1.8 ± 0.49-3.1 ± 0.51-3.6 ± 0.55-1.8 ± 0.50
Week 12-3.2 ± 0.53-2.7 ± 0.55-2.4 ± 0.54-3.0 ± 0.55

Adverse events

Collected over Week 12. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
MT-8554 1mg0/95 (0%)0/95 (0%)37/95 (38.9%)
MT-8554 5mg0/90 (0%)1/90 (1.1%)41/90 (45.6%)
MT-8554 10mg0/93 (0%)0/93 (0%)46/93 (49.5%)
Placebo0/90 (0%)0/90 (0%)37/90 (41.1%)
Most frequent serious events
Most frequent serious events
EventMT-8554 1mgMT-8554 5mgMT-8554 10mgPlacebo
Transient ischaemic attackNervous system disorders0/951/900/930/90
Most frequent other events
Showing 10 of 147
Most frequent other events
EventMT-8554 1mgMT-8554 5mgMT-8554 10mgPlacebo
ParaesthesiaNervous system disorders0/952/9014/932/90
Paraesthesia oralGastrointestinal disorders0/952/9011/930/90
Feeling hotGeneral disorders0/950/907/930/90
HeadacheNervous system disorders3/951/901/936/90
HypoaesthesiaNervous system disorders0/950/905/930/90
Blood creatine phosphokinase increasedInvestigations3/954/901/931/90
Hypoaesthesia oralGastrointestinal disorders0/952/904/930/90
NasopharyngitisInfections and infestations0/953/900/931/90
Upper respiratory tract infectionInfections and infestations2/953/902/931/90
Urinary tract infectionInfections and infestations1/953/901/932/90

Baseline characteristics

Overall number of baseline participants were number of participants who received at least one study medication which was indicated as "Treated" in the above Participant Flow module. 94 subjects were originally randomized to MT-8554 1mg group; but one subject in the placebo group took one week of MT-8554 1mg treatment in error. For calculation of "Treated" subjects, the subject was counted as MT-8554 1mg group so that "Treated" subjects in MT-8554 1 mg group was 95 subjects.

Age, Continuous
Age, Continuous(years)MT-8554 1mgMT-8554 5mgMT-8554 10mgPlaceboTotal
Mean54.5 ± 6.2754.6 ± 6.6256.0 ± 6.5555.7 ± 6.2555.2 ± 6.43
Sex: Female, Male
Sex: Female, Male(Participants)MT-8554 1mgMT-8554 5mgMT-8554 10mgPlaceboTotal
Female95909390368
Male00000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)MT-8554 1mgMT-8554 5mgMT-8554 10mgPlaceboTotal
American Indian or Alaska Native01001
Asian00000
Native Hawaiian or Other Pacific Islander00000
Black or African American2025192892
White74647462274
More than one race00000
Unknown or Not Reported10001
08

Study locations

63 sites
  • Research Site
    Birmingham, Alabama 35209, United States
  • Research Site
    Dothan, Alabama 36303, United States
  • Research Site
    Phoenix, Arizona 85032, United States
  • Research Site
    Norwalk, California 90650, United States
  • Research Site
    Sacramento, California 95821, United States
  • Research Site
    San Diego, California 92111, United States
  • Research Site
    Denver, Colorado 80209, United States
  • Research Site
    New London, Connecticut 06320, United States
  • Research Site
    New London, Connecticut 33176, United States
  • Research Site
    Aventura, Florida 33180, United States
  • Research Site
    Clearwater, Florida 33759, United States
  • Research Site
    Crystal River, Florida 34429, United States
  • Research Site
    Fort Myers, Florida 33912, United States
  • Research Site
    Hialeah, Florida 33012, United States
  • Research Site
    Hialeah, Florida 33016, United States
  • Research Site
    Jacksonville, Florida 32216, United States
  • Research Site
    Jacksonville, Florida 32256, United States
  • Research Site
    Jupiter, Florida 33458, United States
  • Research Site
    Miami, Florida 33176, United States
  • Research Site
    Miami, Florida 33185, United States
  • Research Site
    Miami, Florida 33186, United States
  • Research Site
    Orlando, Florida 32801, United States
  • Research Site
    Orlando, Florida 32806, United States
  • Research Site
    Ponte Vedra, Florida 32081, United States
  • Research Site
    Port Saint Lucie, Florida 34952, United States
  • Research Site
    Sarasota, Florida 34231, United States
  • Research Site
    Sarasota, Florida 34239, United States
  • Research Site
    Wellington, Florida 33414, United States
  • Research Site
    West Palm Beach, Florida 33409, United States
  • Research Site
    Sandy Springs, Georgia 30328, United States
  • Research Site
    Idaho Falls, Idaho 83404, United States
  • Research Site
    Ankeny, Iowa 50023, United States
  • Research Site
    Wichita, Kansas 67226, United States
  • Research Site
    Marrero, Louisiana 70072, United States
  • Research Site
    Metairie, Louisiana 70001, United States
  • Research Site
    Baltimore, Maryland 21208, United States
  • Research Site
    Kalamazoo, Michigan 49009, United States
  • Research Site
    Saginaw, Michigan 48504, United States
  • Research Site
    Saginaw, Michigan 48604, United States
  • Research Site
    Kansas City, Missouri 64114, United States
  • Research Site
    Missoula, Montana 59808, United States
  • Research Site
    Las Vegas, Nevada 89113, United States
  • Research Site
    Las Vegas, Nevada 89128, United States
  • Research Site
    Lawrenceville, New Jersey 08648, United States
  • Research Site
    Morehead City, North Carolina 28557, United States
  • Research Site
    Winston-Salem, North Carolina 27103, United States
  • Research Site
    Cleveland, Ohio 44122, United States
  • Research Site
    Columbus, Ohio 43213, United States
  • Research Site
    Columbus, Ohio 43231, United States
  • Research Site
    Englewood, Ohio 45322, United States
  • Research Site
    Philadelphia, Pennsylvania 19114, United States
  • Research Site
    Bristol, Tennessee 37620, United States
  • Research Site
    Jackson, Tennessee 38305, United States
  • Research Site
    Knoxville, Tennessee 37920, United States
  • Research Site
    Memphis, Tennessee 38119, United States
  • Research Site
    Fort Worth, Texas 76104, United States
  • Research Site
    Schertz, Texas 78154, United States
  • Research Site
    Draper, Utah 84020, United States
  • Research Site
    Ogden, Utah 84403, United States
  • Research Site
    Salt Lake City, Utah 84107, United States
  • Research Site
    Norfolk, Virginia 23502, United States
  • Research Site
    Covington, Washington 98042, United States
  • Research Site
    Seattle, Washington 98105, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2017 to primary completion in Oct 2018, 12 months.

Results were first posted in Jan 2022, 3 years 2 months after primary completion. A results delay was requested in Oct 2019.

Of 24 phase 2 interventional studies under Hot Flashes, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 54. This study's 12 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 20, 2017
First posted
Sep 25, 2017
StartActual
Oct 9, 2017
Primary completionActual
Oct 19, 2018
CompletionActual
Nov 9, 2018
Results delay requested
Oct 16, 2019
Results first posted
Jan 4, 2022
Last update
Jan 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 23, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03291067
Responsible party
Sponsor
First posted
Sep 25, 2017
Start date
Oct 9, 2017
Primary completion
Oct 19, 2018
Completion
Nov 9, 2018
Results posted
Jan 4, 2022
Last update
Jan 23, 2026

Study contacts

Head of Medical Science
study director · Tanabe Pharma America, Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Elismetrep

Start the discussion